BridgeBio Pharma, Inc. · NASDAQ:BBIO

BridgeBio Pharma — Technical Presentation (October 2023)

12 slides from BridgeBio Pharma's technical presentation, October 2023

  1. Slide 1: Acoramidis Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy

    #AHA23 ACORAMIDIS IMPROVES CLINICAL OUTCOMES IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY Daniel P. Judge, MD | Medical University of South Carolina Authors: Daniel P. Judge, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Simon Gibbs, Martha Grogan, Mazen Hanna, Ahmad Masri, Mathew S. Maurer,

  2. Slide 2: Updated Disclosures

    UPDATED DISCLOSURES In the past 3 years, Daniel Judge MD has received payments as an advisor or consultant to ADRx, Alleviant Medical, Astra Zeneca, BridgeBio, Capricor, Cytokinetics, Pfizer, Novo Nordisk, and Tenaya Therapeutics. Acoramidis is an investigational molecule. The safety and efficacy ha

  3. Slide 3: Acoramidis: A 2nd Generation, Potent, Oral TTR Stabilizer for ATTR-CM

    ACORAMIDIS: A 2ND GENERATION, POTENT, ORAL TTR STABILIZER FOR THE TREATMENT OF ATTR-CM Native TTR Dissociation into Monomers circulates in blood monomers initiates aggregate, causing as a tetramer pathogenesis disease ~130 known destabilizing mutations Disease mechanism Protective T119M mutation The

  4. Slide 4: Ph. 3 Study (ATTRibute-CM): Study Design

    PH. 3 STUDY (ATTRIBUTE-CM): STUDY DESIGN 30-month primary endpoint: Hierarchical analysis consisting of all-cause mortality, Key cumulative frequency of CVH, change from baseline in eligibility NT-proBNP, and change from baseline in 6MWD criteria Open-label extension 800 mg Acoramidis HCl twice dail

  5. Slide 5: ATTRibute-CM: Baseline Demographic Characteristics

    ATTRIBUTE-CM: BASELINE DEMOGRAPHIC CHARACTERISTICS Characteristic Acoramidis (N=421) Placebo (N=211) Age (years), mean (SD) 77.4 (6.5) 77.1 (6.8) Male sex, n (%) 384 (91.2) 186 (88.2) ATTRwt-CM, n(%) 380 (90.3) 191 (90.5) NT-proBNP (pg/mL), median (IQR) [nl <300] 2326 (1332, 4019) 2306 (1128, 3754)

  6. Slide 6: Results Achieved on Primary and Select Secondary Endpoints

    RESULTS ACHIEVED ON PRIMARY AND SELECT SECONDARY ENDPOINTS Primary endpoint1 p-value Hierarchical analysis (F-S test1) consisting of: • All-cause mortality2 • Cumulative frequency of CVH p<0.0001 • Change from baseline in NT-proBNP • Change from baseline in 6MWD 58% of ties broken by first Win Ratio

  7. Slide 7: Composite ACM/CVH: Time-to-First Event & F-S Test

    COMPOSITE ACM/CVH: TIME-TO-FIRST EVENT & F-S TEST K-M curves separate early, at Month 3, and steadily diverge through Month 30 Hazard Ratio: 0.645 95% CI: 0.500-0.832 p value = 0.0008 Number Needed to Treat (NNT) to avoid a death or first CVH over 2.5 years 7 Favors acoramidis over placebo 2-Compone

  8. Slide 8: Cumulative Frequency of CV Hospitalizations: 50% Reduction with Acoramidis

    CUMULATIVE FREQUENCY OF CV HOSPITALIZATIONS (CVH): 50% REDUCTION WITH ACORAMIDIS Acoramidis Placebo (N=409) (N=202) Number of subjects with CVH1 109 (26.7%) 86 (42.6%) Frequency CVH per year (modeled)2 Mean (95% CI) 0.22 (0.18-0.28) 0.45 (0.35-0.58) Relative Risk Ratio (95% CI) 0.496 (0.355-0.695) p

  9. Slide 9: No Safety Signals of Potential Clinical Concern Identified

    NO SAFETY SIGNALS OF POTENTIAL CLINICAL CONCERN IDENTIFIED Acoramidis Placebo N=421 N=211 Subjects with one or more event(s) N (%) N (%) Any treatment-emergent adverse events (TEAEs) 413 (98.1%) 206 (97.6%) TEAE with fatal outcome 60 (14.3%) 36 (17.1%) TEAE leading to hospitalization 212 (50.4%) 128

  10. Slide 10: Putting Results in Context

    PUTTING RESULTS IN CONTEXT • These contemporary data reset clinical expectations in the treatment and management of today’s ATTR-CM patients, who are diagnosed earlier and live longer • Mortality rate of ATTRibute-CM placebo (25.7%) less than ATTR-ACT tafamidis (29.5%) • Outcomes in acoramidis treat

  11. Slide 11: Conclusion: Acoramidis Improves Clinical Outcomes in ATTR-CM

    CONCLUSION: ACORAMIDIS IMPROVES CLINICAL OUTCOMES IN ATTR-CM ATTRibute-CM study results demonstrate that acoramidis improves clinical outcomes (All-Cause Mortality/CV Hospitalization) in ATTR-CM patients: • Primary Endpoint (4-component F-S analysis) showed a significant treatment benefit of acorami

  12. Slide 12: Thank You

    THANK YOU QD American =, Scientific #AHA23 Association. “EY Sessions

BridgeBio Pharma — Technical Presentation (October 2023) on 6ix